Beta Bionics (NASDAQ:BBNX) Shares Climb 3.8% - Here's What Happened

Key Points

• Beta Bionics shares rose 3.8% to about $18.30 in midday trading, though volume was approximately 89% below the average session level.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $24.00; targets range from $16.00 to $30.00.
• The company exceeded quarterly EPS expectations, reporting a loss of $0.53 per share versus the expected $0.62 loss, but it continues to post negative margins and return on equity. Insiders have sold roughly $1.91 million in shares over the past 90 days.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report)'s share price shot up 3.8% during mid-day trading on Monday. The company traded as high as $18.28 and last traded at $18.2950. Approximately 130,957 shares were traded during mid-day trading, a decline of 89% from the average session volume of 1,179,003 shares. The stock had previously closed at $17.63.

Analyst Ratings Changes

Several research firms have weighed in on BBNX. William Blair assumed coverage on shares of Beta Bionics in a report on Friday, August 21st. They set a "market perform" rating on the stock. UBS Group reiterated a "buy" rating and set a $25.00 price objective on shares of Beta Bionics in a report on Tuesday, September 15th. Robert W. Baird lifted their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the company a "neutral" rating in a report on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Finally, Barclays initiated coverage on shares of Beta Bionics in a report on Tuesday, October 6th. They issued an "overweight" rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Beta Bionics currently has an average rating of "Moderate Buy" and an average price target of $24.00.

Beta Bionics Price Performance

The company has a market cap of $823.63 million, a P/E ratio of -11.10 and a beta of 3.39. The stock has a fifty day moving average price of $18.76 and a two-hundred day moving average price of $15.01.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Equities analysts predict that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Stephen Feider sold 6,675 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the sale, the chief financial officer owned 159,378 shares in the company, valued at $3,045,713.58. This represents a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the sale, the director owned 19,564 shares of the company's stock, valued at approximately $449,972. This represents a 24.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 97,697 shares of company stock worth $1,907,034. Company insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BBNX. Squarepoint Ops LLC purchased a new stake in Beta Bionics in the 2nd quarter valued at about $2,524,000. Bank of America Corp DE bought a new position in shares of Beta Bionics during the 2nd quarter worth approximately $8,566,000. Man Group plc bought a new position in shares of Beta Bionics during the 2nd quarter worth approximately $419,000. Legal & General Group Plc purchased a new position in shares of Beta Bionics in the 2nd quarter worth approximately $62,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Beta Bionics in the 2nd quarter worth approximately $172,000.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company's dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person's body weight and meal announcements as key inputs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.